Pharmacological validation of candidate causal sleep genes identified in an N2 cross

Journal of Neurogenetics

Volumn 25, Issue 4, 2011, Pages 167-181

  Brunner, Joseph I ^a   Gotter, Anthony L ^a   Millstein, Joshua ^b,e   Garson, Susan ^a   Binns, Jacquelyn ^c   Fox, Steven V ^c   Savitz, Alan T ^c   Yang, He S ^d   Fitzpatrick, Karrie ^d   Zhou, Lili ^d   Owens, Joseph R ^d   Webber, Andrea L ^a   Vitaterna, Martha H ^d   Kasarskis, Andrew ^b,f   Uebele, Victor N ^c   Turek, Fred ^d   Renger, John J ^a   Winrow, Christopher J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ROSETTA INPHARMATICS   (United States)

^c Department of in Vivo Pharmacology ^*  (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f PACIFIC BIOSCIENCES   (United States)

Author keywords

Genetics; Pharmacology; Rodent; Sleep; Translation

Indexed keywords

1 [2 [4 (4 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N METHYLISOCHROMAN 6 CARBOXAMIDE; 3 [4 (3 CHLOROPHENYL) 1 PIPERAZINYL] 1,1 DIPHENYL 2 PROPANOL; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CALCIUM CHANNEL T TYPE; CALCIUM CHANNEL T TYPE ALPHA 1I SUBUNIT; CYTISINE; DARIFENACIN; DOPAMINE 5 RECEPTOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LIRAGLUTIDE; MUSCARINIC M3 RECEPTOR; NICOTINIC RECEPTOR ALPHA4; PILOCARPINE; RISPERIDONE; SEROTONIN 1D RECEPTOR; SUMATRIPTAN; UNCLASSIFIED DRUG; VARENICLINE;

AGONIST; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE TARGETING; LOCOMOTION; LOW DRUG DOSE; MALE; NONHUMAN; PHARMACOLOGICAL PARAMETERS; POLYSOMNOGRAPHY; PRIORITY JOURNAL; RAT; REM SLEEP; RODENT; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP; SLEEP DEPRIVATION; SLEEP PARAMETERS; SLEEP WAKING CYCLE; SLOW WAVE SLEEP; VALIDATION STUDY;

ANIMALS; CALCIUM CHANNELS, P-TYPE; CALCIUM CHANNELS, Q-TYPE; CROSSES, GENETIC; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, MUSCARINIC M3; RECEPTORS, DOPAMINE D5; RECEPTORS, NICOTINIC; SLEEP; SLEEP DISORDERS;

ANIMALIA; MAMMALIA; RODENTIA;

EID: 81555207964     PISSN: 01677063     EISSN: 15635260     Source Type: Journal    
DOI: 10.3109/01677063.2011.628426     Document Type: Article

References (54)

1. Bourne, J. A. (2001). SCH 23390: The fi rst selective dopa mine D-1-like receptor antagonist. CNS Drug Rev, 7, 399-414.
2. Brisbare-Roch, C., Dingemanse, J., Koberstein, R., Hoever, P., Aissaoui, H., Flores, S., et al. (2007). Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med, 13, 150-155.
3. Broman, K. W., Wu, H., Sen, S., & Churchill, G. A. (2003). R/qtl: QTL mapping in experimental crosses. Bioinformatics, 19, 889-890.
4. Caylak, E. (2009). The genetics of sleep disorders in humans: Narcolepsy, restless legs syndrome, and obstructive sleep apnea syndrome. Am J Med Genet.A, 149A, 2612-2626.
5. Chabas, D., Taheri, S., Renier, C., & Mignot, E. (2003). The genetics of narcolepsy. Annu Rev Genomics Human Genet, 4, 459-483.
6. Cirelli, C. (2009). The genetic and molecular regulation of sleep: From fruit fl ies to humans. Nat Rev Neurosci, 10, 549-560.
7. Cirelli, C., Gutierrez, C. M., & Tononi, G. (2004). Extensive and divergent effects of sleep and wakefulness on brain gene expression. Neuron, 41, 35-43.
8. Cohrs, S. (2008). Sleep disturbances in patients with schizophrenia impact and effect of antipsychotics. CNS Drugs, 22, 939-962.
9. Compta, Y., Santamaria, J., Ratti, L., Tolosa, E., Iranzo, A., Munoz, E., et al. (2009). Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson ' s disease dementia. Brain, 132, 3308-3317.
10. Cutrer, F. M., Yu, X. J., Ayata, G., Moskowitz, M. A., & Waeber, C. (1999). Effects of PNU-109,291, a selective 5-HT1D receptor agonist, on electrically induced dural plasma extravasation and capsaicin-evoked c-fos immunoreactivity within trige minal nucleus caudalis. Neuropharmacology, 38, 1043-1053.
11. Dani, J. A., & Bertrand, D. (2007). Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol, 47, 699-729.
12. Dauviltiers, Y., Maret, S., & Tafti, M. (2005). Genetics of normal and pathological sleep in humans. Sleep Med Rev, 9, 91-100.
13. Devineni, D., Skerjanec, A., & Woodworth, T. G. (2005). Low central nervous system (CNS) penetration by darifenacin, a muscarinic M3 selective receptor antagonist, in rats pA2. Online E-J Br Pharmacol Soc, 3, A092.
14. Di Fabio, R., Pellacani, A., Faedo, S., Roth, A., Piccoli, L., Gerrard, P., et al. (2011). Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders. Bioorgan Med Chem Lett, 21, 5562-5567.
15. Franken, P., & Tafti, M. (2003). Genetics of sleep and sleep disorders. Front Biosci, 8, E381-E397.
16. Gonzales, D., Rennard, S. I., Nides, M., Oncken, C., Azoulay, S., Billing, C. B., et al. (2006). Varenicline, an alpha 4 beta 2 nicotinic acetylcholine receptor partial agonist, vs sustainedrelease bupropion and placebo for smoking cessation - A randomized controlled trial. JAMA, 296, 47-55.
17. Hagan, J. J., Slade, P. D., Gaster, L., Jeffrey, P., Hatcher, J. P., & Middlemiss, D. N. (1997). Stimulation of 5-HT1B receptors causes hypothermia in the guinea pig. Eur J Pharmacol, 331, 169-174.
18. Hallmayer, J., Faraco, J., Lin, L., Hesselson, S., Winkelmann, J., Kawashima, M., et al. (2009). Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet, 41, 708-711.
19. Hayes, M. R., Kanoski, S. E., Alhadeff, A. L., & Grill, H. J. (2011). Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats. Obesity, 19, 1342-1349.
20. Hor, H., Kutalik, Z., Dauvilliers, Y., Valsesia, A., Lammers, G. J., Donjacour, C. E. H. M., et al. (2010). Genome-wide association study identifi es new HLA class II haplo types strongly protective against narcolepsy. Nat Genet, 42, 786-789.
21. Jiang, P., Striz, M., Wisor, J. P., & O ' Hara, B. F. (2011). Behavioral and genetic dissection of a mouse model for advanced sleep phase syndrome. SLEEP, 34, 39-48.
22. Kanoski, S. E., Fortin, S. M., Arnold, M., Grill, H. J., & Hayes, M. R. (2011). Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology, 152, 3103-3112.
23. Kayser, V., Aubel, B., Hamon, M., & Bourgoin, S. (2002). The antimigraine 5-HT1B/1D receptor agonists, sumatriptan, zolmitriptan and dihydroergotamine, attenuate pain-related behaviour in a rat model of trigeminal neuropathic pain. Br J Pharmacol, 137, 1287-1297.
24. Kornum, B. R., Kawashima, M., Faraco, J., Lin, L., Rico, T. J., Hesselson, S., et al. (2011). Common variants in P2RY11 are associated with narcolepsy. Nat Genet, 43, 66-U90.
25. Lin, L., Faraco, J., Li, R., Kadotani, H., Rogers, W., Lin, X. Y., et al. (1999). The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell, 98, 365-376.
26. Mackiewicz, M., Shockley, K. R., Romer, M. A., Galante, R. J., Zimmerman, J. E., Naidoo, N., et al. (2007). Macromolecule biosynthesis: A key function of sleep. Physiol Genomics, 31, 441-457.
27. Mackiewicz, M., Zimmerman, J. E., Shockley, K. R., Churchill, G. A., & Pack, A. I. (2009). What are microarrays teaching us about sleep? Trends Mol Med, 15, 79-87.
28. Millstein, J., Winrow, C. J., Kasarskis, A., Owens, J. R., Zhou, L., Summa, K. C., et al. (2011). Identifi cation of causal genes, networks and transcriptional regulators of REM sleep and wake. SLEEP, 34, 1469-1477.
29. Millstein, J., Zhang, B., Zhu, J., & Schadt, E. E. (2009). Disentangling molecular relationships with a causal inference test. BMC Genetics, 10, 23.
30. Missale, C., Nash, S. R., Robinson, S. W., Jaber, M., & Caron, M. G. (1998). Dopamine receptors: From structure to function. Physiol Rev, 78, 189-225.
31. Miyagawa, T., Kawashima, M., Nishida, N., Ohashi, J., Kimura, R., Fujimoto, A., et al. (2008). Variant between CPT1B and CHKB associated with susceptibility to narcolepsy. Nat Genet, 40, 1324-1328.
32. Nishino, S., & Okuro, M. (2010). Emerging treatments for narcolepsy and its related disorders. Expert Opin Emerg Drugs, 15, 139-158.
33. Pauwels, P. J., & John, G. W. (1999). Present and future of 5-HT receptor agonists as antimigraine drugs. Clin Neuropharmacol, 22, 123-136.
34. Peterson, M. J., & Benca, R. M. (2006). Sleep in mood disorders. Psychiatr Clin N Am, 29, 1009-1032 .
35. Pinheiro, J.C., and Bates, D.M. (2000) Mixed-Effects Models in S and S-PLUS, Springer, New York, USA. Renger, J. J., Dunn, S. L., Motzel, S. L., Johnson, C., & Koblan, K. S. (2004). Sub-chronic administration of zolpidem affects modifi cations to rat sleep architecture. Brain Res, 1010, 45-54.
36. Sajja, R. K., & Rahman, S. (2011). Lobeline and cytisine reduce voluntary ethanol drinking behavior in male C57BL/6J mice. Progress Neuro-Psychopharmacol Biol Psychiatry, 35, 257-264.
37. Saper, C. B., Scammell, T. E., & Lu, J. (2005). Hypothalamic regulation of sleep and circadian rhythms. Nature, 437, 1257-1263.
38. Schadt, E. E., Lamb, J., Yang, X., Zhu, J., Edwards, S., GuhaThakurta, D., et al. (2005). An integrative genomics approach to infer causal associations between gene expression and disease. Nat Genet, 37, 710-717.
39. Sehgal, A., & Mignot, E. (2011). Genetics of sleep and sleep disorders. Cell, 146, 194-207.
40. 2+ channel antagonist. J Med Chem, 51, 3692-3695.
41. Slassi, A., Isaac, M., & Arora, J. (2001). Novel serotonergic and non-serotonergic migraine headache therapies. Exp Opin Therapeut Patents, 11, 625-649.
42. Tafti, M. (2009). Genetic aspects of normal and disturbed sleep. Sleep Med, 10(Suppl 1), S17-S21.
43. Thompson, C. L., Wisor, J. P., Lee, C. K., Pathak, S. D., Gerashchenko, D., Smith, K. A., et al. (2010). Molecular and anatomical signatures of sleep deprivation in the mouse brain. Front Neurosci, 4, 165.
44. Tononi, G., & Cirelli, C. (2003). Sleep and synaptic homeostasis: A hypothesis. Brain Res Bull, 62, 143-150.
45. Uebele, V. N., Gotter, A. L., Nuss, C. E., Kraus, R. L., Doran, S. M., Garson, S. L., et al. (2009). Antagonism of T-type calcium channels inhibits high-fat diet-induced weight gain in mice. J Clin Invest, 119, 1659-1667.
46. Venables, W. N., & Ripley, B. D. (2002). Modern Applied Statistics with S. (4th ed.) New York: Springer.
47. Vilaro, M. T., Palacios, J. M., & Mengod, G. (1994). Multiplicity of muscarinic autoreceptor subtypes - Comparison of the distribution of cholinergic cells and cells containing messenger-RNA for 5 subtypes of muscarinic receptors in the rat-brain. Mol Brain Res, 21, 30-46.
48. Whitman, D. B., Cox, C. D., Breslin, M. J., Brashear, K. M., Schreier, J. D., Bogusky, M. J., et al. (2009). Discovery of a potent, CNS-penetrant orexin receptor antagonist based on an N , N -disubstituted-1,4-diazepane scaffold that promotes sleep in rats. Chemmedchem, 4, 1069-1074.
49. Winrow, C. J., Gotter, A. L., Cox, C. D., Doran, S. M., Tannenbaum, P. L., Breslin, M. J., et al. (2011). Promotion of sleep by suvorexant - A novel dual orexin receptor antagonist. J Neurogenet, 25, 52-61.
50. Winrow, C. J., Williams, D. L., Kasarskis, A., Millstein, J., Laposky, A. D., Yang, H. S., et al. (2009). Uncovering the genetic landscape for multiple sleep-wake traits. PLoS One, 4 , e5161.
51. Yin, X. P., Wei, D. Z., Yi, L. N., Tao, X. Y., & Ma, Y. S. (2005). Expression and purifi cation of exendin-4, a GLP-1 receptor agonist, in Escherichia coli . Prot Express Purif, 41, 259-265.
52. Zaniewska, M., McCreary, A. C., Stefanski, R., Przegalinski, E., & Filip, M. (2008). Effect of varenicline on the acute and repeated locomotor responses to nicotine in rats. Synapse, 62, 935-939.
53. Zee, P. C., & Turek, F. W. (2006). Sleep and health - Everywhere and in both directions. Arch Intern Med, 166, 1686-1688.
54. Zhang, C., Fang, Y. R., & Li, M. (2011). Olanzapine and risperidone disrupt conditioned avoidance responding by selectively weakening motivational salience of conditioned stimulus: Further evidence. Pharmacol Biochem Behav, 98, 155-160.